Introduction: After is infected with the new coronavirus, human organs may aging for 3-5 years; after Eli Lilly acquired US$487 million, Akouos' stock price rose by 86%; Mablink received 31 million euros Series A financing, expanding the ADCh pipeline... Biological Exploration will follow the "medicine" news with you and explore the value of biotechnology!
01 After infection with the new coronavirus
Human organs may age for 3-5 years
According to ABC, after about two and a half years of research, scientists have confirmed that the human organs after infection with the new coronavirus will undergo tremendous changes in . "Infection with the new coronavirus is an accelerator of aging, so viral infection will accelerate the aging process in people."
Dr. Ali collected data from millions of people across the United States. The data shows that the aging rate of multiple organs of COVID-19 patients is accelerating, especially among hospitalized patients with COVID-19, but this can also occur in some patients with mild COVID-19 patients. Dr. Ali said: "In just one year, the human organs have almost aged for 3 to 4 years." The results show that in the year after the infection with the new coronavirus, the patients' renal function will drop by about 3% to 4%.
Although more years of data are needed, Dr. Ali believes that this intensifying aging process will eventually stop. Judging from the current data, this situation will eventually become smoother.
02 After the acquisition of Eli Lilly for US$487 million,
Akouos' stock price rose 86%
On October 18, Eli Lilly announced that it will acquire Boston biotech company Akouos at a premium of 78% over the closing price of on Monday. As of 22:00 Beijing time, Akouos's stock price rose 86%, with a market value of US$259 million. In the first half of the year, the company's operating expenses were US$95 million, of which R&D expenses were US$34.7 million, and cash and equivalents were US$73.58 million; Eli Lilly's US$487 million was a timely help for Akouos.
Akouos has been committed to adeno-associated virus gene therapy to treat inner ear disease and hearing loss. Its pioneer project AK-OTOF attempts to treat hearing loss caused by mutations in the otoferlin gene. AK-OTOF received its first IND license last month, and the Phase I/II trial is being planned, but the timeline has not been determined. Other pipeline projects are designed for other genetic hearing loss situations.
The biotech company went public at $17 per share during the Covid-19 pandemic in June 2020. The company's shares had fallen to $2.32 earlier this year, but have rebounded in recent months. For Eli Lilly to plan the field of gene therapy, this is a developing story, and the layout may be updated in the future.
03 Mablink received 31 million euros in
Series A financing, expanded ADC pipeline
Recently, Mablink Bioscience announced that it had raised 31 million euros in Series A financing, led by Sofinnova Partners and Mérieux Equity Partners. The financing prompted Mablink to invest its main candidate drug MBK-103 in the clinical development of solid tumor (especially ovarian cancer) treatment, making it a clinical-stage biotech company. At the same time, Mablink will establish an ADC R&D pipeline for solid tumors.
Mablink Bioscience ("Mablink") is a biotechnology company that aims to change cancer treatment methods using next-generation antibody-drug conjugates (ADCs).
04 Duchenne muscular dystrophy new drug
applied for marketing in EU
Recently, Switzerland's Santhera Pharmaceutical Company announced that it has submitted a marketing authorization application (MAA) for the treatment of Duchenne muscular dystrophy (DMD) to European Medicines Agency (EMA). In the United States, the company is expected to submit a new drug application for vamorolone for the treatment of DMD (NDA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2022.
vamorolone is a first-in-class, dissociative steroid with a new mode of action. It has been awarded the Orphan Drug Qualification (ODD) for the treatment of DMD in the United States and Europe, and has been awarded the Fast Track Qualification (FTD) and Rare Pediatric Disease Qualification (RPDD) of the U.S. FDA, and the title of "Potential Innovation Drug (PIM)" by the UK Drug and Health Products Administration (MHRA).
Duchenne muscular dystrophy (DMD) is a rare hereditary X-chromosome chain disease that affects almost only men. DMD is characterized by an inflammatory response at or shortly after birth, leading to muscle fibrosis, clinically manifested as progressive muscle degeneration and weakness. Key milestones in the progression of DMD disease include loss of walking ability, loss of self-feeding, initiation of assisted ventilation, and the development of cardiomyopathy . Due to respiratory and/or heart failure , life expectancy for patients with DMD is usually no more than 40 years.
05 Eli Lilly's new obesity drug
has obtained the FDA fast track qualification
Recently, Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has granted Mounjaro (tirzepatide) fast track qualification (FTD): used to treat obese or overweight adult patients with weight-related comorbidities.
Mounjaro is a novel, weekly GIP and GLP-1 receptor agonist that was approved by the U.S. FDA in May 2022: assisted diet and exercise to improve blood sugar control in adult patients with type 2 diabetes (T2D). It is worth mentioning that Mounjaro is the first GIP/GLP-1 receptor agonist approved by the US FDA. This drug also represents the first new type of hypoglycemic drug approved for marketing in the past decade.
Organized|Wensheng
Typeset|Wensheng
End
